Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 188


Increased serum vWF and sVCAM-1 levels are associated with late or very late angiographic stent thrombosis after sirolimus-eluting stent implantation.

Jin C, Lu L, Zhu ZB, Zhang RY, Zhang Q, Du R, Ding FH, Chen QJ, Shen WF.

Coron Artery Dis. 2010 Aug;21(5):273-7. doi: 10.1097/MCA.0b013e32833b20f1.


Drug-eluting stent thrombosis 1,659 days after stent deployment: case report and literature review.

Al-Dehneh A, Virk H, Alkhouri Y, Hamdan A, Bikkina M.

Tex Heart Inst J. 2010;37(3):343-6. Review.


Stent malapposition after sirolimus-eluting and bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: acute and 9-month intravascular ultrasound results of the MISSION! intervention study.

van der Hoeven BL, Liem SS, Dijkstra J, Bergheanu SC, Putter H, Antoni ML, Atsma DE, Bootsma M, Zeppenfeld K, Jukema JW, Schalij MJ.

JACC Cardiovasc Interv. 2008 Apr;1(2):192-201. doi: 10.1016/j.jcin.2008.02.003.


Safety and efficacy of biodegradable polymer-coated sirolimus-eluting stents in "real-world" practice: 18-month clinical and 9-month angiographic outcomes.

Han Y, Jing Q, Xu B, Yang L, Liu H, Shang X, Jiang T, Li Z, Zhang H, Li H, Qiu J, Liu Y, Li Y, Chen X, Gao R; CREATE (Multi-Center Registry of Excel Biodegradable Polymer Drug-Eluting Stents) Investigators.

JACC Cardiovasc Interv. 2009 Apr;2(4):303-9. doi: 10.1016/j.jcin.2008.12.013.


Late restenosis following sirolimus-eluting stent implantation.

Kuriyama N, Kobayashi Y, Nakama T, Mine D, Nishihira K, Shimomura M, Nomura K, Ashikaga K, Matsuyama A, Shibata Y.

JACC Cardiovasc Interv. 2011 Jan;4(1):123-8. doi: 10.1016/j.jcin.2010.09.013.


The PASEO (PaclitAxel or Sirolimus-Eluting Stent Versus Bare Metal Stent in Primary Angioplasty) Randomized Trial.

Di Lorenzo E, De Luca G, Sauro R, Varricchio A, Capasso M, Lanzillo T, Manganelli F, Mariello C, Siano F, Pagliuca MR, Stanco G, Rosato G.

JACC Cardiovasc Interv. 2009 Jun;2(6):515-23. doi: 10.1016/j.jcin.2009.03.012.


Sirolimus-eluting stents versus bare-metal stents in routine clinical use: a nonrandomized comparison.

Munir M, Aliota J, Ahmed A, Mohammed A, Lee VV, Elayda MA, Wilson JM.

Tex Heart Inst J. 2011;38(5):508-15.


Extremely late drug-eluting stent thrombosis: 2037 days after deployment.

Layland J, Jellis C, Whitbourn R.

Cardiovasc Revasc Med. 2009 Jan-Mar;10(1):55-7. doi: 10.1016/j.carrev.2008.05.001.


Incidence and predictors of very late (>or=4 years) major cardiac adverse events in the DESIRE (Drug-Eluting Stents in the Real World)-Late registry.

Costa JR Jr, Sousa A, Moreira AC, Costa RA, Cano M, Maldonado G, Campos C, Carballo M, Pavanello R, Sousa JE.

JACC Cardiovasc Interv. 2010 Jan;3(1):12-8. doi: 10.1016/j.jcin.2009.10.022.


Safety and efficacy of 2.5-mm sirolimus-eluting stent implantation at lower deployment pressures in very small vessels (<2.5 mm).

Umeda H, Iwase M, Gochi T, Izawa H, Ishiki R, Inagaki H, Shimizu T, Yokota M, Murohara T.

Coron Artery Dis. 2009 Mar;20(2):163-8. doi: 10.1097/MCA.0b013e328329dc20.


Three-year prognosis of Japanese patients with ST-elevation myocardial infarction treated with sirolimus-eluting stents.

Yoshikawa D, Isobe S, Umeda H, Kawai T, Shimizu T, Yamashita K, Ishii H, Murohara T.

Coron Artery Dis. 2009 Sep;20(6):422-7. doi: 10.1097/MCA.0b013e32832fa92c.


The unrestricted use of sirolimus- and paclitaxel-eluting stents results in better clinical outcomes during 6-year follow-up than bare-metal stents: an analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated At Rotterdam Cardiology Hospital) registries.

Simsek C, Magro M, Boersma E, Onuma Y, Nauta ST, Gaspersz MP, van der Giessen WJ, van Domburg RT, Serruys PW; Interventional Cardiologists of the Thoraxcenter.

JACC Cardiovasc Interv. 2010 Oct;3(10):1051-8. doi: 10.1016/j.jcin.2010.08.003.


Comparison of drug-eluting and bare-metal stents for primary percutaneous coronary intervention with or without abciximab in ST-segment elevation myocardial infarction: DEBATER: the Eindhoven reperfusion study.

Wijnbergen I, Helmes H, Tijssen J, Brueren G, Peels K, van Dantzig JM, Van' t Veer M, Koolen JJ, Pijls NH, Michels R.

JACC Cardiovasc Interv. 2012 Mar;5(3):313-22. doi: 10.1016/j.jcin.2011.11.009.


Randomized comparison of everolimus-eluting stents and sirolimus-eluting stents in patients with ST elevation myocardial infarction: RACES-MI trial.

Di Lorenzo E, Sauro R, Varricchio A, Capasso M, Lanzillo T, Manganelli F, Carbone G, Lanni F, Pagliuca MR, Stanco G, Rosato G, Suryapranata H, De Luca G.

JACC Cardiovasc Interv. 2014 Aug;7(8):849-56. doi: 10.1016/j.jcin.2014.02.016.


The 5352 A allele of the pro-inflammatory caspase-1 gene predicts late-acquired stent malapposition in STEMI patients treated with sirolimus stents.

Bergheanu SC, Pons D, van der Hoeven BL, Liem SS, Siegerink B, Schalij MJ, van der Bom JG, Jukema JW.

Heart Vessels. 2011 May;26(3):235-41. doi: 10.1007/s00380-010-0046-8. Epub 2010 Oct 30.


Real polymer-free sirolimus- and probucol-eluting versus biodegradable polymer sirolimus-eluting stents for obstructive coronary artery disease: DKPLUS-Wave 1, a multicenter, randomized, prospective trial.

Chen SL, Ye F, Zhang JJ, Zou JJ, Qian XS, Li F, Yang S, Ge Z, Shan SJ, Li XB, Xu T, Kan J, Lin L, Han YL.

Cardiovasc Ther. 2013 Aug;31(4):193-200. doi: 10.1111/j.1755-5922.2012.00319.x.


Activation of the immune system and inflammatory activity in relation to markers of atherothrombotic disease and atherosclerosis in rheumatoid arthritis.

Wållberg-Jonsson S, Cvetkovic JT, Sundqvist KG, Lefvert AK, Rantapää-Dahlqvist S.

J Rheumatol. 2002 May;29(5):875-82.


Gender-based evaluation of the XIENCE V everolimus-eluting coronary stent system: clinical and angiographic results from the SPIRIT III randomized trial.

Lansky AJ, Ng VG, Mutlu H, Cristea E, Guiran JB, Midei M, Newman W, Sanz M, Sood P, Doostzadeh J, Su X, White R, Cao S, Sudhir K, Stone GW.

Catheter Cardiovasc Interv. 2009 Nov 1;74(5):719-27. doi: 10.1002/ccd.22067.


Supplemental Content

Support Center